Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence …
Treatment With Prolia(R) (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence …
Thousand Oaks, California (ots/PRNewswire) – Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia(R) (denosumab) treatment than during …
Read more on Presseportal
Categories: Breast Cancer Information Tags: Adherence, Associated, Compliance, Denosumab, Greater, Persistence, ProliaR, significantly, Treatment
Amgen Presents New XGEVA (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Amgen Presents New XGEVA (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
Amgen today announced results from new analyses comparing XGEVA⢠, the first new treatment for advanced cancer patients with bone metastases in nearly a decade to prevent skeletal-related events, to Zometa® .
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Pain Tags: Amgen, breast, cancer, Data, Denosumab, event, presents, Prevention, SABCS, SkeletalRelated, XGEVA
Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With …
Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With …
THOUSAND OAKS, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ — Amgen (Nasdaq: AMGN) today announced the publication of results from a pivotal Phase 3 study of 2,046 patients which compared denosumab with Zometa® (zoledronic acid) in delaying or preventing skeletal-related events (SREs) in breast cancer patients with bone metastases. An SRE consists of any of the following: a pathologic fracture …
Read more on redOrbit
Categories: Breast Cancer Tumor Tags: bone, Complications, Delaying, Denosumab, Patients, Preventing, Published, Results, Show, Superior, Zometa®
Amgen gets rapid FDA review for denosumab
Amgen gets rapid FDA review for denosumab
(AP:THOUSAND OAKS, Calif.) Federal regulators will conduct a rapid review of Amgen’s treatment for bone damage suffered by cancer patients.
Read more on INO News
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal …
FDA Grants Priority Review Designation to Denosumab Biologics License Application for the Reduction of Skeletal …
Amgen today announced that the U.S. Food and Drug Administration has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events in patients with cancer.
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Risks Tags: application, Biologics, Denosumab, Designation, Grants, License, priority, reduction, Review, Skeletal